Radj Gervais

17.8k total citations · 3 hit papers
83 papers, 5.2k citations indexed

About

Radj Gervais is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Radj Gervais has authored 83 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 56 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Radj Gervais's work include Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Radj Gervais is often cited by papers focused on Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Radj Gervais collaborates with scholars based in France, United States and Canada. Radj Gervais's co-authors include Frances A. Shepherd, Joachim von Pawel, Filippo de Marinis, Miklos Pless, Paolo Paoletti, Thomas Chang Yao Tsao, Paul A. Bunn, Christian Manegold, Sofia Paul and Thomas Müller and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Radj Gervais

81 papers receiving 5.1k citations

Hit Papers

Randomized Phase III Trial of Pemetrexed Versus Docetaxel... 2004 2026 2011 2018 2004 2008 2021 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
    2004 1.9k citations Radj Gervais et al. Journal of Clinical Oncology profile →
  2. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    2008 1.0k citations Radj Gervais et al. profile →
  3. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    2021 201 citations Radj Gervais, Margarita Majem et al. Journal of Thoracic Oncology profile →

Peers

Radj Gervais
Mircea Dediu Romania
Hiroaki Akamatsu Japan
Mark S. Huberman United States
Masahiro Tabata Japan
Sang-We Kim South Korea
Shinzoh Kudoh Japan
Jin‐Ji Yang China
Renato Martins United States
Willemijn S.M.E. Theelen Netherlands
Chong‐Rui Xu China
Mircea Dediu Romania
Radj Gervais
Citations per year, relative to Radj Gervais Radj Gervais (= 1×) peers Mircea Dediu

Countries citing papers authored by Radj Gervais

Since Specialization
Citations

This map shows the geographic impact of Radj Gervais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radj Gervais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radj Gervais more than expected).

Fields of papers citing papers by Radj Gervais

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radj Gervais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radj Gervais. The network helps show where Radj Gervais may publish in the future.

Co-authorship network of co-authors of Radj Gervais

This figure shows the co-authorship network connecting the top 25 collaborators of Radj Gervais. A scholar is included among the top collaborators of Radj Gervais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radj Gervais. Radj Gervais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.
2.
Dupont, Benoît, Bénédicte Clarisse, Jean‐Jacques Parienti, et al.. (2023). Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab. BMC Cancer. 23(1). 32–32. 3 indexed citations
3.
Eberst, Guillaume, Amélie Anota, Arnaud Scherpereel, et al.. (2019). Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research. 25(19). 5759–5765. 15 indexed citations
4.
5.
Lesueur, Paul, Alexandre Escande, Juliette Thariat, et al.. (2018). Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Medicine. 7(11). 5505–5513. 36 indexed citations
6.
Baut, Guillaume Le, Jean‐Marc Guilloit, Yann Ollivier, et al.. (2018). Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. Journal of Gastrointestinal Oncology. 9(3). E15–E18. 1 indexed citations
7.
Gervais, Radj, D. De Raucourt, E. Babin, et al.. (2017). Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy. European Archives of Oto-Rhino-Laryngology. 274(7). 2883–2889. 6 indexed citations
8.
Johnson, Alison, Pascal Dô, Nicolas Richard, et al.. (2016). Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA. Lung Cancer. 99. 38–40. 8 indexed citations
9.
Sassier, Marion, B. Mennecier, Antoine Coquerel, et al.. (2016). Successful treatment with ceritinib after crizotinib induced hepatitis. Lung Cancer. 95. 15–16. 12 indexed citations
10.
Costa, Carlota, Miguel Angel Molina, Ana Drozdowskyj, et al.. (2014). The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. Clinical Cancer Research. 20(7). 2001–2010. 180 indexed citations
11.
Blanchard, D., et al.. (2014). Cancer de l’oropharynx. Bulletin du Cancer. 101(5). 429–437. 5 indexed citations
12.
Lasnon, Charline, Cédric Desmonts, Elske Quak, et al.. (2013). Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 40(7). 985–996. 88 indexed citations
13.
Icard, Philippe, Françoise Galateau-Sallé, P Rosat, et al.. (2013). Does Bilobectomy Offer Satisfactory Long-Term Survival Outcome for Non-Small Cell Lung Cancer?. The Annals of Thoracic Surgery. 95(5). 1726–1733. 5 indexed citations
14.
15.
Mariotte, Delphine, Benoît Dupont, Radj Gervais, et al.. (2011). Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. mAbs. 3(4). 396–401. 41 indexed citations
16.
Zatloukal, Petr, Radj Gervais, Johan Vansteenkiste, et al.. (2008). Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(8). 894–901. 22 indexed citations
17.
Pujol, Jean Louis, Radj Gervais, Marie‐Laure Tanguy, et al.. (2007). Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01. Journal of Clinical Oncology. 25(25). 3945–3951. 97 indexed citations
18.
19.
Courthéoux, P., et al.. (2003). Stent placement in superior vena cava syndrome. The Annals of Thoracic Surgery. 75(1). 158–161. 30 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by Hiroaki Akamatsu Breakdown of academic impact, for papers by Mark S. Huberman Breakdown of academic impact, for papers by Masahiro Tabata Breakdown of academic impact, for papers by Sang-We Kim Breakdown of academic impact, for papers by Shinzoh Kudoh Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Chong‐Rui Xu
Rankless by CCL
2026